Khan Ayesha, Khan Maryam, Rana Muhammad Owais, Haque Md Ariful
Dow University of Health Sciences, Karachi, Pakistan.
Department of Public Health, Atish Dipankar University of Science and Technology, Dhaka, Bangladesh.
Ann Med Surg (Lond). 2025 Apr 25;87(6):3073-3075. doi: 10.1097/MS9.0000000000003325. eCollection 2025 Jun.
Mantle cell lymphoma (MCL) is a rare disorder that comprises 5-10% of non-Hodgkin's lymphoma, with an increasing incidence of about 1-2 cases per 100 000 people. It is characterized by cyclin D1 mutation. The intricate genomic landscape and cells' proliferation history contribute to its clinical heterogeneity. Multiple treatments often result in relapse and resistance owing to various mutations. To overcome the need for therapies in patients with relapsed/refractory (R/R) МСL, amidst increasing resistance to other treatment options, the Food and Drug Administration (FDA) approved Lisocabtagene Maraleucel (Lіѕо-Сеl) on 30 May 2024. In the clinical trial, Lisocabtagene Maraleucel showcased a high response rate and a manageable safety profile. However, severe adverse events were also observed, highlighting the need for risk and mitigation analysis before administration. Additionally, long-term studies evaluating its comparative efficacy and safety against existing therapies are needed, and more defined guidelines for managing high-risk patients are required.
套细胞淋巴瘤（MCL）是一种罕见疾病，占非霍奇金淋巴瘤的5%-10%，发病率呈上升趋势，约为每10万人中有1-2例。其特征为细胞周期蛋白D1突变。复杂的基因组格局和细胞增殖史导致了其临床异质性。由于各种突变，多种治疗方法常常导致复发和耐药。为了满足复发/难治性（R/R）MCL患者的治疗需求，在对其他治疗选择的耐药性不断增加的情况下，美国食品药品监督管理局（FDA）于2024年5月30日批准了利索卡妥基因马罗芦卡（Liso-Cel）。在临床试验中，利索卡妥基因马罗芦卡显示出高缓解率和可控的安全性。然而，也观察到了严重不良事件，这凸显了给药前进行风险和缓解分析的必要性。此外，需要进行长期研究以评估其与现有疗法相比的疗效和安全性，并且需要更明确的高危患者管理指南。
